Non-invasive apparatus system for monitoring drug hepatoxicity and uses thereof

• US 7,074,190 B2
• Filed: 10/06/2003
• Issued: 07/11/2006
• Est. Priority Date: 10/09/2002
• Status: Expired due to Fees

• Current Assignee: Industrial Technology Research Institute
• Original Assignee: Industrial Technology Research Institute
• Inventors: Sun, Dehchuan
• Primary Examiner(s): NASSER, ROBERT L
• Application Number:
  US10/679,741
• Publication Number:
  US 20040073121A1
• Time in Patent Office: 1,009 Days
• Field of Search: 600/485, 600/490, 600493-496, 600500-503, 600/300
• US Class Current: 600/485
• CPC Class Codes: A61B 5/0002 Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network A61B5/07 takes precedence; transmission systems for measured values G08C; transmission H04B; transmission of digital information H04L; wireless communication networks H04W
• CPC Class Codes: A61B 5/021 Measuring pressure in heart or blood vessels A61B5/0205 takes precedence
• CPC Class Codes: A61B 5/02108 from analysis of pulse wave characteristics

Abstract

The invention relates to a non-invasive apparatus system for monitoring drug hepatotoxicity, and its uses in monitoring drug-induced hepatotoxicity and abnormal liver function.

Claims

1. A non-invasive apparatus system for monitoring drug hepatotoxicity or drug-induced abnormal liver function comprising:

(a) a sensor for measuring artery blood pressure waveforms to form electric waves representing the artery blood pressure waveforms; and

(b) an analyzer for receiving the electric waves from (a), the electric waves obtained before and after drug intake being calculated by mathematical formulas;

wherein if any altered amounts of any or some of the electric waves are between two certain preset values or higher than a preset value, the analyzer determines that the drug has induced a certain level of liver function change or the drug has induced a severe liver function change; and

then a warning device comprised in the analyzer will emit warning signals.

2. The apparatus system according to claim 1, wherein the sensor is a pressure sensory device or one or more electrode chips.

3. The apparatus system according to claim 2, wherein the pressure sensory device is an apparatus worn on wrist to measure the blood pressure waveform of radial artery.

4. A method for monitoring drug hepatotoxicity or drug-induced abnormal liver function, the method comprising utilizing the apparatus system of claim 3.

5. A method for monitoring drug hepatotoxicity or drug-induced abnormal liver function, the method comprising utilizing the apparatus system of claim 2.

6. The apparatus system according to claim 1, wherein the analyzer further comprises a display device for showing the analyzing data and results recorded in the analyzer.

7. A method for monitoring drug hepatotoxicity or drug-induced abnormal liver function, the method comprising utilizing the apparatus system of claim 6.

8. The apparatus system according to claim 1, wherein the analyzer further comprises an apparatus, which can transfer the measured and analyzed data to a terminal at hospital'"'"'s or doctor'"'"'s end, and the apparatus can further receive the signals transferred from the hospital or doctor.

9. A method for monitoring drug hepatotoxicity or drug-induced abnormal liver function, the method comprising utilizing the apparatus system of claim 8.

10. The apparatus system according to claim 8, wherein the signal is transferred in a wired or wireless way.

11. A method for monitoring drug hepatotoxicity or drug-induced abnormal liver function, the method comprising utilizing the apparatus system of claim 10.

12. A method for monitoring drug hepatotoxicity or drug-induced abnormal liver function, the method comprising utilizing the apparatus system of claim 1.

13. The apparatus system according to claim 1, wherein the electric waves comprise waveform parameters including a number of wave peaks, a major wave peak point, a major wave trough point, a minor wave peak point, and/or a minor trough point, time parameters, pressure parameters, oblique angle parameters, superficial measure parameters, and/or ratio parameters.

14. A method for monitoring drug hepatotoxicity or drug-induced abnormal liver function, the method comprising utilizing the apparatus system of claim 13.

15. A non-invasive apparatus system for monitoring drug hepatotoxicity or drug-induced abnormal liver function comprising:

a wrist type sphygmomanometer which uses a pressure sensory element to transform radial artery blood pressure waveform of a patient'"'"'s arm to electric waves;

a bedside recording analyzer which can receive, amplify, filter, and analog-digital transform the electric waves from the sphygmomanometer, wherein the analyzer comprises a small computer to record and analyze the electric waves obtained before and after drug intake by mathematical formulas;

wherein if any altered amounts of any or some of the electric waves are between two certain preset values or higher than a preset value, the drug has induced a certain level of liver function change or the drug has induced a severe liver function change; and

an information server and a terminal machine which can send the information from the analyzer to a hospital or clinic for a doctor'"'"'s diagnosis, and send back instructions from the doctor to the patient'"'"'s bedside record analyzer.

16. A method for monitoring drug hepatotoxicity or drug-induced abnormal liver function, the method comprising utilizing the apparatus system of claim 15.

17. The apparatus system according to claim 15, wherein the electric waves comprise waveform parameters including a number of wave peaks, a major wave peak point, a major wave trough point, a minor wave peak point, and/or a minor trough point, time parameters, pressure parameters, oblique angle parameters, superficial measure parameters, and/or ratio parameters.

18. A method for monitoring drug hepatotoxicity or drug-induced abnormal liver function, the method comprising utilizing the apparatus system of claim 17.